Supernus Pharmaceuticals Inc (SUPN)
Stock-Based Compensation
$58.00M
TTM · Period ending: · USD
SUPN Stock-Based Compensation
Latest reported$58.00Mperiod ending
Latest reported$58.00Mperiod ending
SUPN TTM Stock-Based Comp (-$82.00K → $58.00M)
TTM stock-based compensation
High-resolution chart · PNG
SUPN stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 57,996,000 | |
| 56,863,000 | |
| 56,451,000 | |
| 31,032,000 | |
| 30,881,000 | |
| 29,926,000 | |
| 27,755,000 | |
| 26,568,000 | |
| 26,814,000 | |
| 26,350,000 | |
| 26,759,000 | |
| 24,575,000 | |
| 21,640,000 | |
| 19,849,000 | |
| 17,568,000 | |
| 17,343,000 | |
| 16,385,000 | |
| 17,564,000 | |
| 17,910,000 | |
| 16,995,000 | |
| 17,458,000 | |
| 16,944,000 | |
| 16,561,000 | |
| 17,063,000 | |
| 16,487,000 | |
| 15,547,000 | |
| 14,846,000 | |
| 14,214,000 | |
| 12,897,000 | |
| 11,943,000 | |
| 11,291,000 | |
| 10,286,000 | |
| 10,049,000 | |
| 9,241,000 | |
| 8,433,000 | |
| 7,919,000 | |
| 7,042,000 | |
| 6,394,000 | |
| 5,926,000 | |
| 5,533,000 | |
| 5,182,000 | |
| 4,547,000 | |
| 4,090,000 | |
| 3,704,000 | |
| 3,378,000 | |
| 3,053,000 | |
| 2,818,000 | |
| 2,778,000 | |
| 2,463,000 | |
| 2,243,000 | |
| 1,913,000 | |
| 1,468,000 | |
| 1,107,000 | |
| 728,000 | |
| 443,000 | |
| 197,000 | |
| 115,000 | |
| 110,000 | |
| -82,000 | |
| 129,008 | |
| 108,977 |